Isotechnika retains global rights to transplant drug
Isotechnika will now open up the licensing process to companies with a strategic focus in this therapeutic area. The licensing process will be completed based on an accelerated
Teva Pharmaceuticals International and Polpharma Biologics have signed a global licensing agreement for a proposed biosimilar to Ocrevus (ocrelizumab) to treat multiple sclerosis (MS).